CytoMed Therapeutics announce that the CAR-gamma delta T cell technology, which it has exclusively licensed from A*STAR, has been granted a patent by the US Patent and Trademark Office, USPTO. The patent titled “Gamma Delta T Cells and a Method of Augmenting the Tumoricidal Activity of the Same” covers technologies for the clinical-scale expansion of gammadelta T cells from a small amount of donor peripheral blood cells as well as the modification of the expanded gammadelta T cells to incorporate a chimeric antigen receptor that enables the modified cells to recognize a wide range of cancers, including both solid and hematologic cancers. “We are pleased to announce our allogeneic CAR-gammadelta T cell technology has received a US patent especially when we are soon to embark on our first-in-human trial for CAR-gammadelta T cells in Singapore,” said Peter Choo, Chairman of CytoMed. “We expect to receive additional patent rights from other territories.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>